Literature DB >> 2916553

Effect of human immunodeficiency virus (HIV) antibody knowledge on high-risk sexual behavior with steady and nonsteady sexual partners among homosexual men.

G J van Griensven1, E M de Vroome, R A Tielman, J Goudsmit, F de Wolf, J van der Noordaa, R A Coutinho.   

Abstract

For the study of the impact of human immunodeficiency virus (HIV) antibody testing on high-risk sexual behavior with nonsteady and steady sexual partners, 307 homosexual men (118 seronegative, 75 seropositive, and 114 untested) were interviewed at three consecutive six-month intervals between July 1985 and December 1986. From the results, it appears that among seropositives the percentage who performed anogenital insertive intercourse with nonsteady partners remained constant (73, 64, and 61% during the first, second, and third intervals, respectively (nonsignificant]. Among seronegatives and those who were untested, the percentages who practiced anogenital receptive intercourse with nonsteady partners decreased from 44 to 29% and from 54 to 20%, respectively (p less than 0.05). The percentage who performed anogenital insertive intercourse and anogenital receptive intercourse with their steady partner remained constant in all groups: seropositives, +/- 70%; seronegatives, +/- 60%; and untested, +/- 55%. Seropositives were more likely to use condoms during anogenital insertive intercourse with their nonsteady and steady sexual partners than were seronegatives and untested persons during anogenital receptive intercourse with these partners (p less than 0.05). In the majority of cases, condoms were not used antibody testing in the three groups studied. The generalizability of these results, however, is limited.

Entities:  

Mesh:

Year:  1989        PMID: 2916553     DOI: 10.1093/oxfordjournals.aje.a115172

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  12 in total

1.  Periodic health examination, 1992 update: 3. HIV antibody screening. Canadian Task Force on the Periodic Health Examination.

Authors: 
Journal:  CMAJ       Date:  1992-09-15       Impact factor: 8.262

2.  HIV.

Authors:  E J Smit
Journal:  Sex Transm Infect       Date:  2006-12       Impact factor: 3.519

3.  Reduction of high-risk sexual behavior among heterosexuals undergoing HIV antibody testing: a randomized clinical trial.

Authors:  N S Wenger; L S Linn; M Epstein; M F Shapiro
Journal:  Am J Public Health       Date:  1991-12       Impact factor: 9.308

4.  Behavioral interventions for the primary prevention of HIV infection among homosexual and bisexual men.

Authors:  P L Peterson; D G Ostrow; D J McKirnan
Journal:  J Prim Prev       Date:  1991-09

5.  [AIDS prevention in homosexuals in Switzerland: adaptation to risks according to type of partner].

Authors:  F Moreau-Gruet; F Dubois-Arber
Journal:  Soz Praventivmed       Date:  1996

6.  Modelling the effect of treatment and behavioral change in HIV transmission dynamics.

Authors:  J X Velasco-Hernandez; Y H Hsieh
Journal:  J Math Biol       Date:  1994       Impact factor: 2.259

7.  Effects of HIV counseling and testing on sexual risk behavior: a meta-analytic review of published research, 1985-1997.

Authors:  L S Weinhardt; M P Carey; B T Johnson; N L Bickham
Journal:  Am J Public Health       Date:  1999-09       Impact factor: 9.308

8.  HIV testing in adolescents and young adults receiving STI testing in an urban primary care setting.

Authors:  Renata Arrington-Sanders; Jonathan Ellen; Maria Trent
Journal:  Sex Transm Dis       Date:  2008-07       Impact factor: 2.830

9.  Responses to anonymous questionnaires concerning sexual behavior: a method to examine potential biases.

Authors:  R J Biggar; M Melbye
Journal:  Am J Public Health       Date:  1992-11       Impact factor: 9.308

10.  Behavior changes after notification of HIV infection.

Authors:  P D Cleary; N Van Devanter; T F Rogers; E Singer; R Shipton-Levy; M Steilen; A Stuart; J Avorn; J Pindyck
Journal:  Am J Public Health       Date:  1991-12       Impact factor: 9.308

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.